HALOZYME THERAPEUTICS, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
HALOZYME THERAPEUTICS, INC. (HALO) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $9.96 million as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-17
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $9.96M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.57M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.02M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.35M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $9.96M 10-K · filed 2026-02-17 |
| 2024-12-31 | $6.57M 10-K · filed 2026-02-17 |
| 2023-12-31 | $5.02M 10-K · filed 2025-02-18 |
| 2022-12-31 | $6.35M 10-K · filed 2024-02-20 |
| 2021-12-31 | $1.81M 10-K · filed 2023-02-21 |
| 2020-12-31 | $4.64M 10-K · filed 2022-02-22 |
| 2019-12-31 | $9.97M 10-K · filed 2021-02-23 |
| 2018-12-31 | $9.54M 10-K · filed 2020-02-24 |
| 2017-12-31 | $7.42M 10-K · filed 2019-02-21 |
| 2016-12-31 | $8.84M 10-K · filed 2018-02-20 |
| 2015-12-31 | $6.29M 10-K · filed 2017-02-28 |
| 2014-12-31 | $5.38M 10-K · filed 2016-02-29 |
| 2013-12-31 | $2.50M 10-K · filed 2015-03-02 |
| 2012-12-31 | $2.98M 10-K · filed 2014-02-28 |
| 2011-12-31 | $2.12M 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |